Skip to main content

Table 3 Clinicopathological features

From: Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas

 

All patients (n=60)

BRCA1 (n=3)

BRCA2 (n=25)

BRCAX (n=32)

P-value

AGE AT DIAGNOSIS

     

Median

62.5 (30.1 - 85.6)

65.6 (49.5-80.1)

61 (31.0 - 85.7)

63.2 (30.1 - 81.8)

 

<60 yoa

26 (43.3%)

1 (33.3%)

11 (44.0%)

14 (43.8%)

 

>60 yoa

34 (56.7%)

2 (66.6%)

14 (56.0%)

18 (56.3%)

NS

DISEASE SPECIFIC MORTALITY

35.0%

33.3%

40.0%

31.3%

 

SIDE

     

Right

36 (60.0%)

1 (33.3%)

17 (68.0%)

18 (56.2%)

 

Left

24 (40.0%)

2 (66.7%)

8 (32.0%)

14 (43.8%)

NS

Unifocal

56 (93.3%)

3 (100%)

22 (88.0%)

31 (96.9%)

 

Multifocal

2 (3.3%)

0

2 (8.0%)

0

 

Bilateral

2 (3.3%)

0

1 (4.0%)

1 (3.1%)

NS

HISTOLOGICAL SUBTYPE

     

Invasive Ductal Carcinoma - No special type

46 (76.7%)

2 (66.7%)

18 (72%)

28 (87.5%)

 

IDC with Micropapillary component

8 (13.3%)

0

6 (24%)

2 (6.3%)

 

Invasive Papillary Carcinoma

4 (6.7%)

1 (33.3%)

1 (4%)

2 (6.3%)

 

Invasive Lobular Carcinoma

2 (3.3%)

0

0

2 (6.3%)

NS

BRE GRADE

     

1

2 (3.3%)

0

1 (4%)

1 (3.1%)

 

2

31 (51.7%)

0

12 (48%)

19 (59.4%)

 

3

27 (45.0%)

3 (100%)

12 (48%)

12 (37.5%)

NS

ER STATUS (ALLRED 0-8)

     

0

1 (1.7%)

0

0

1 (3.3%)

 

1-5.

5 (8.6%)

1 (33.3%)

2 (8.0%)

2 (6.7%)

 

6-8.

52 (89.7%)

2 (66.7%)

23 (92.0%)

27 (90.0%)

 

NA

2

0

0

2

NS

PR STATUS (ALLRED 0-8)

     

0

5 (8.8%)

0

1 (4%)

4 (13.8%)

 

1-5.

8 (14.0%)

0

5 (20%)

3 (10.3%)

 

6-8.

44 (77.2%)

3 (100%)

19 (76%)

22 (75.9%)

 

NA

3

0

0

3

NS

HER2

     

Amplification

5 (9.1%)

0

2 (8.3%)

3 (10.7%)

 

Non-amplified

50 (90.9%)

3 (100%)

22 (91.7%)

25 (89.3%)

 

NA

5

0

1

4

NS

PHENOTYPE

     

Basal

1 (1.7%)

0

0

1 (3.3%)

 

Luminal

52 (89.7%)

3 (100%)

23 (92.0%)

26 (86.7%)

 

HER2

5 (8.6%)

0

2 (8.0%)

3 (10.0%)

 

NA

2

0

0

2

NS

TUMOUR SIZE

     

Median

17mm (2-50mm)

15mm (9-25mm)

17mm (6-40mm)

16 (2-50mm)

 

TUMOUR STAGE

     

T1a

1 (1.7%)

0

0

1 (3.1%)

 

T1b

8 (13.3%)

1 (33.3%)

4 (16.0%)

3 (9.4%)

 

T1c

31 (51.7%)

1 (33.3%)

10 (40.0%)

19 (59.4%)

 

T2

19 (31.7%)

1 (33.3%)

11 (44.0%)

7 (21.9%)

 

T3

1 (1.7%)

0

0

1

NS

LYMPHOVASCULAR INVASION

     

Absent

32 (57.1%)

2 (66.7%)

14 (60.9%)

16 (53.3%)

 

Present

24 (42.9%)

1 (33.3%)

9 (39.1%)

14 (46.7%)

 

NA

4

0

2

2

NS

PERINEURAL INVASION

     

Absent

31 (56.4%)

3 (100%)

12 (50.0%)

16 (57.1%)

 

Present

24 (43.6%)

0

12 (50.0%)

12 (42.9%)

 

NA

5

0

1

4

NS

PAGET'S DISEASE OF NIPPLE

     

Absent

44 (84.6%)

2 (100%)

19 (86.4%)

23 (82.1%)

 

Present

8 (15.4%)

0

3 (13.6%)

5 (17.9%)

 

NA

8

1

3

4

NS

NODAL STATUS

     

Cases with nodes examined

46 (76.7%)

3 (100%)

20 (80.0%)

23 (71.9%)

 

Cases with positive nodes

20 (43.4%)

2 (66.7%)

9 (45.0%)

9 (39.1%)

NS

Average numbers of nodes examined per case

12.9 (1-30)

16.3 (13-24)

15.9 (1-30)

10.1 (1-29)

 

NODAL STAGE

     

N0

26 (56.5%)

1 (33.3%)

11 (55.0%)

14 (60.1%)

 

N1

18 (39.1%)

2 (66.7%)

8 (40.0%)

8 (34.8%)

 

N2

2 (4.3%)

0

1 (5.0%)

1 (4.3%)

NS

Cases with extranodal extension

8 (17.4%)

0

5 (25.0%)

3 (13.0%)

NS

MARGINS

     

Clear

29 (48.3%)

1 (33.3%)

12 (48.0%)

16 (50.0%)

 

Involved

15 (25.0%)

0

6 (24.0%)

9 (28.1%)

 

Not assessable

16 (26.7%)

2 (66.7%)

7 (28.0%)

7 (21.9%)

NS

DCIS

     

Absent

14 (25.0%)

0

7 (29.2%)

7 (24.1%)

 

NA

4

0

1

3

 

Present

42 (75.0%)

3 (100%)

17 (70.8%)

22 (75.9%)

NS

Nuclear Grade

     

Low

2 (4.8%)

0

2 (11.8%)

0

 

Intermediate

26 (61.9%)

1 (33.3%)

10 (58.8%)

15 (68.0%)

 

High

14 (33.3%)

2 (66.7%)

5 (29.4%)

7 (31.8%)

NS

  1. NS – Not significant.